An Early Phase 1 interventional study of [O-15]Water and Acetazolamide in Validation of a New Noninvasive Method to Obtain the Arterial Input Function (AIF) Directly by PET Imaging, sponsored by University of Alabama at Birmingham. Withdrawn at 1 site in United States. Open to participants aged 19 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-01.
Sponsored by University of Alabama at Birmingham · Early Phase 1, Interventional, and Basic science
The overall aim of this project is to implement a non-invasive method of measuring quantitative regional cerebral blood flow (rCBF) on the UAB hybrid PET/MRI scanner to allow conducting such [O-15]water based scans with relative ease and safety in a large variety of important clinical and research applications. Participants will undergo imaging at baseline and after administration of a drug to increase cerebral blood flow to evaluate perfusion estimates during low and high flow states. The goal of this study is to generate data that will justify eliminating invasive arterial sampling in most [O-15]water-based PET protocols.
University of Alabama at Birmingham is the lead sponsor of 1,396 studies on the registry; 284 are open to participants now.
Of its 156 completed or terminated interventional studies of FDA-regulated products, 124 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Volunteers will have two brain PET/MRI scans; first scan after injection of \[O-15\]water; second scan after injection of 1 gram of acetazolamide followed by injection of \[O-15\]water.
Drug: [O-15]Water · Drug: Acetazolamide
All study participants with undergo brain imaging with \[O-15\]water-PET/MRI without and with administration of the carbonic anhydrase inhibitor acetazolamide. The PET tracer will be used to measure regional cerebral perfusion, and the administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
The administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
Also known as: Diamox
Comparison of arterial sampling to non-invasive methods to measure regional cerebral blood flow using [O-15]water-PET/MRI
Measurements of regional cerebral blood flow with \[O-15\]water-PET/MRI using arterial sampling versus non-invasive image-based input function estimates will be compared.
Time frame: 3 years
This study is withdrawn, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama at Birmingham